CALY-001 is a best-in-class fully human monoclonal antibody inhibiting Matrix Metalloproteinase 9 (MMP-9). MMP-9 degrades extracellular matrix (ECM) proteins and processes a number of bioactive molecules. MMP-9 is involved in several biological pathways, such as cell migration, angiogenesis, inflammation, tissue remodeling and fibrosis. As a result, MMP-9 is an attractive target for multiple pathologies, from auto-immune and inflammatory diseases to fibrotic diseases and cancers. CALY-001 was out-licensed to Japan-based EA Pharma in 2017.
CALY-002 is a best-in-class humanized monoclonal antibody inhibiting Interleukin-15 (IL-15). IL-15 is a cytokine mainly expressed by monocytes, dendritic cells and epithelial cells. IL-15 plays multiple roles in the immune system by controlling the homeostasis and activation of T, B, NK and tissue resident memory T cells. CALY-002 is well positioned as paradigm-changing treatment for several gastrointestinal indications with currently no approved treatment, as well as other large immune pathologies.